These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23943142)

  • 21. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
    Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
    Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
    Lin JC; Shau WY; Lai MS
    Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
    Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
    Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the role of insulin detemir in Basal insulin therapy.
    Morales J
    Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: trial comparing insulin detemir with insulin glargine.
    Swinnen S; Holleman F
    Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
    PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
    Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
    Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin detemir: a long-acting insulin product.
    Jones MC; Patel M
    Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feline diabetes mellitus: clinical use of long-acting glargine and detemir.
    Bloom CA; Rand J
    J Feline Med Surg; 2014 Mar; 16(3):205-15. PubMed ID: 24563492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.
    Elisha B; Azar M; Taleb N; Bernard S; Iacobellis G; Rabasa-Lhoret R
    Horm Metab Res; 2016 Jan; 48(1):42-7. PubMed ID: 26340704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.